Profound Medical Corp. performed its first commercial use of the TULSA‑PRO system at Johns Hopkins Hospital on January 6, 2026, marking the first time the technology has been applied outside of clinical trials. The procedure was carried out in the hospital’s new interventional MRI suite, allowing the company to showcase the system’s real‑time MRI thermography and closed‑loop temperature control in a high‑profile setting.
The TULSA‑PRO procedure delivers robotically controlled ultrasound from inside the urethra to heat prostate tissue to 55‑57 °C while MRI thermography monitors temperature and protects surrounding nerves. The system offers incision‑free, radiation‑free treatment with no procedural blood loss, no overnight stay and rapid recovery, positioning it as a competitive alternative to radical prostatectomy and external‑beam radiation. The technology also incorporates AI‑driven planning and contouring, which were cleared by the FDA in 2024 and 2023, respectively, and has been CE‑marked and approved by Health Canada.
Profound’s recent financial performance underscores the commercial momentum behind the launch. In Q3 2025 the company reported revenue of $5.3 million, an 87 % increase year‑over‑year, and a gross margin of 74.3 %. The growth was driven by strong demand for the TULSA‑PRO platform in both prostate cancer and benign prostatic hyperplasia indications, offsetting the company’s ongoing investments in commercialization and AI development. In late 2025 Profound secured additional capital through registered direct offerings and private placements to support the expansion of its sales force and to fund continued R&D, reinforcing its balance sheet and enabling the company to pursue broader market penetration.
CEO Arun Menawat said the Johns Hopkins deployment “is a milestone that demonstrates the clinical value of TULSA‑PRO and confirms the system’s readiness for routine use.” He added that the partnership with a leading academic center “strengthens our position in the prostate disease market and provides a high‑profile endorsement that will accelerate adoption at other institutions.” The company’s strategy now focuses on scaling commercial sales in North America while building distribution partnerships in Australia and New Zealand, and on exploring additional therapeutic indications such as uterine fibroids and bone metastases with its Sonalleve platform.
The commercial debut at Johns Hopkins signals a shift from clinical validation to market adoption for Profound. With the first commercial case completed, the company is positioned to capture a share of the growing demand for minimally invasive prostate treatments, a market that is expanding as patients and payers seek alternatives to surgery and radiation. The event also reinforces Profound’s competitive moat, as the combination of MRI‑guided precision, AI integration, and a proven safety profile differentiates TULSA‑PRO from other ablative therapies. The company’s recent financial gains and capital raising activities provide the resources needed to accelerate this expansion, while the partnership with a top-tier academic center enhances credibility and may catalyze further institutional adoptions.
The launch at Johns Hopkins represents a pivotal moment for Profound Medical, marking the transition from clinical trials to routine clinical practice and setting the stage for broader commercialization of its TULSA‑PRO platform across the United States and internationally.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.